General form of registration statement for all companies including face-amount certificate companies

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT

v3.21.2
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - USD ($)
Evolv Technologies Holdings, Inc.
Common Stock
Adoption of ASU 2018-07 and ASU 2019-08 (Note 1)
Evolv Technologies Holdings, Inc.
Common Stock
Evolv Technologies Holdings, Inc.
Additional Paid-in Capital
Evolv Technologies Holdings, Inc.
Accumulated Deficit
Evolv Technologies Holdings, Inc.
Adoption of ASU 2018-07 and ASU 2019-08 (Note 1)
Evolv Technologies Holdings, Inc.
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2018           $ 43,441,000      
Balance at the beginning (in shares) at Dec. 31, 2018           114,375,397      
Convertible Preferred Stock [Abstract]                  
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $938           $ 22,363,000      
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $105 (in shares)           63,785,925      
Conversion of convertible note into Series B-1 convertible preferred stock           $ 6,595,000      
Conversion of convertible note into Series B-1 convertible preferred stock (in shares)           18,056,296      
Balance at the end at Dec. 31, 2019         $ (484,000) $ 72,883,000      
Balance at the end (in shares) at Dec. 31, 2019         484 196,217,618     196,217,618
Balance at the beginning at Dec. 31, 2018   $ 23,000 $ 8,145,000 $ (46,632,000)   $ (38,464,000)      
Balance at the beginning (in shares) at Dec. 31, 2018   22,499,825              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     3,000     3,000      
Issuance of common stock upon exercise of stock options   $ 0 28,000     28,000      
Issuance of common stock upon exercise of stock options (in shares)   309,333              
Stock-based compensation expense     264,000     264,000      
Net loss attributable to common stockholders - basic and diluted       (19,857,000)   (19,857,000)      
Balance at the end at Dec. 31, 2019   $ 23,000 7,956,000 (66,489,000)   (58,510,000)      
Balance at the end (in shares) at Dec. 31, 2019 (484) 22,809,158              
Convertible Preferred Stock [Abstract]                  
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $938           $ 2,994,000      
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $105 (in shares)           8,486,175      
Balance at the end at Mar. 31, 2020           $ 75,877,000      
Balance at the end (in shares) at Mar. 31, 2020           204,703,793      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     45,000     $ 45,000      
Issuance of common stock upon exercise of stock options   $ 1,000 66,000     67,000      
Issuance of common stock upon exercise of stock options (in shares)   744,710              
Stock-based compensation expense     62,000     62,000      
Net loss attributable to common stockholders - basic and diluted       (6,430,000)   (6,430,000)      
Balance at the end at Mar. 31, 2020   $ 24,000 8,129,000 (72,919,000)   (64,766,000) $ 25,000   $ 25,000
Balance at the end (in shares) at Mar. 31, 2020   23,553,868              
Balance at the beginning at Dec. 31, 2019         $ (484,000) $ 72,883,000      
Balance at the beginning (in shares) at Dec. 31, 2019         484 196,217,618     196,217,618
Balance at the end at Jun. 30, 2020           $ 75,877,000      
Balance at the end (in shares) at Jun. 30, 2020           204,703,793      
Balance at the beginning at Dec. 31, 2019   $ 23,000 7,956,000 (66,489,000)   $ (58,510,000)      
Balance at the beginning (in shares) at Dec. 31, 2019 (484) 22,809,158              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock           45,000      
Net loss attributable to common stockholders - basic and diluted           (11,534,000)      
Balance at the end at Jun. 30, 2020   $ 24,000 8,192,000 (78,023,000)   (69,807,000) 25,000 $ (2,000) $ 23,000
Balance at the end (in shares) at Jun. 30, 2020   23,583,034              
Balance at the beginning at Dec. 31, 2019         $ (484,000) $ 72,883,000      
Balance at the beginning (in shares) at Dec. 31, 2019         484 196,217,618     196,217,618
Convertible Preferred Stock [Abstract]                  
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $938           $ 2,994,000      
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $105 (in shares)           8,486,175      
Balance at the end at Dec. 31, 2020           $ 75,877,000     $ 140,774,000
Balance at the end (in shares) at Dec. 31, 2020           204,703,793     14,077,350
Balance at the beginning at Dec. 31, 2019   $ 23,000 7,956,000 (66,489,000)   $ (58,510,000)      
Balance at the beginning (in shares) at Dec. 31, 2019 (484) 22,809,158              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     112,000     112,000      
Issuance of common stock upon exercise of stock options   $ 3,000 439,000     $ 442,000      
Issuance of common stock upon exercise of stock options (in shares)   3,236,374       3,236,374      
Stock-based compensation expense     662,000     $ 662,000      
Net loss attributable to common stockholders - basic and diluted     (27,392,000) (27,392,000)   (27,392,000)      
Balance at the end at Dec. 31, 2020   $ 26,000 9,169,000 (93,881,000)   (84,686,000) 16,912,000 (11,912,000) $ 5,000,000
Balance at the end (in shares) at Dec. 31, 2020   26,045,532              
Balance at the end at Jun. 30, 2020           $ 75,877,000      
Balance at the end (in shares) at Jun. 30, 2020           204,703,793      
Balance at the beginning at Jan. 23, 2020             0 0 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss attributable to common stockholders - basic and diluted               (2,000) (2,000)
Balance at the end at Jun. 30, 2020   $ 24,000 8,192,000 (78,023,000)   $ (69,807,000) 25,000 (2,000) 23,000
Balance at the end (in shares) at Jun. 30, 2020   23,583,034              
Balance at the end at Dec. 31, 2020           $ 75,877,000     $ 140,774,000
Balance at the end (in shares) at Dec. 31, 2020           204,703,793     14,077,350
Balance at the beginning at Jan. 23, 2020             0 0 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock             1,336,000   1,336,000
Net loss attributable to common stockholders - basic and diluted               (11,912,000) (11,912,000)
Balance at the end at Dec. 31, 2020   $ 26,000 9,169,000 (93,881,000)   $ (84,686,000) 16,912,000 (11,912,000) 5,000,000
Balance at the end (in shares) at Dec. 31, 2020   26,045,532              
Balance at the beginning at Mar. 31, 2020           $ 75,877,000      
Balance at the beginning (in shares) at Mar. 31, 2020           204,703,793      
Balance at the end at Jun. 30, 2020           $ 75,877,000      
Balance at the end (in shares) at Jun. 30, 2020           204,703,793      
Balance at the beginning at Mar. 31, 2020   $ 24,000 8,129,000 (72,919,000)   $ (64,766,000) 25,000   25,000
Balance at the beginning (in shares) at Mar. 31, 2020   23,553,868              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of stock options     3,000     3,000      
Issuance of common stock upon exercise of stock options (in shares)   29,166              
Stock-based compensation expense     60,000     60,000      
Net loss attributable to common stockholders - basic and diluted       (5,104,000)   (5,104,000)   (2,000) (2,000)
Balance at the end at Jun. 30, 2020   $ 24,000 8,192,000 (78,023,000)   (69,807,000) 25,000 (2,000) 23,000
Balance at the end (in shares) at Jun. 30, 2020   23,583,034              
Balance at the beginning at Dec. 31, 2020           $ 75,877,000     $ 140,774,000
Balance at the beginning (in shares) at Dec. 31, 2020           204,703,793     14,077,350
Balance at the end at Mar. 31, 2021           $ 75,877,000      
Balance at the end (in shares) at Mar. 31, 2021           204,703,793      
Balance at the beginning at Dec. 31, 2020   $ 26,000 9,169,000 (93,881,000)   $ (84,686,000) 16,912,000 (11,912,000) $ 5,000,000
Balance at the beginning (in shares) at Dec. 31, 2020   26,045,532              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     1,000     1,000      
Issuance of common stock upon exercise of stock options   $ 4,000 451,000     455,000      
Issuance of common stock upon exercise of stock options (in shares)   4,137,451              
Stock-based compensation expense     1,082,000     1,082,000      
Net loss attributable to common stockholders - basic and diluted       (13,755,000)   (13,755,000)      
Balance at the end at Mar. 31, 2021   $ 30,000 10,703,000 (107,636,000)   (96,903,000) 20,994,000 (15,994,000) 5,000,000
Balance at the end (in shares) at Mar. 31, 2021   30,182,983              
Balance at the beginning at Dec. 31, 2020           $ 75,877,000     $ 140,774,000
Balance at the beginning (in shares) at Dec. 31, 2020           204,703,793     14,077,350
Balance at the end at Jun. 30, 2021           $ 75,877,000     $ 129,066,000
Balance at the end (in shares) at Jun. 30, 2021           204,703,793     12,906,585
Balance at the beginning at Dec. 31, 2020   $ 26,000 9,169,000 (93,881,000)   $ (84,686,000) 16,912,000 (11,912,000) $ 5,000,000
Balance at the beginning (in shares) at Dec. 31, 2020   26,045,532              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of stock options (in shares)           5,523,538      
Net loss attributable to common stockholders - basic and diluted           $ (36,126,000)   (11,708,000) (11,708,000)
Balance at the end at Jun. 30, 2021   $ 35,000 11,435,000 (130,007,000)   (118,537,000) 28,620,000 (23,620,000) 5,000,000
Balance at the end (in shares) at Jun. 30, 2021   35,342,394              
Balance at the beginning at Mar. 31, 2021           $ 75,877,000      
Balance at the beginning (in shares) at Mar. 31, 2021           204,703,793      
Balance at the end at Jun. 30, 2021           $ 75,877,000     $ 129,066,000
Balance at the end (in shares) at Jun. 30, 2021           204,703,793     12,906,585
Balance at the beginning at Mar. 31, 2021   $ 30,000 10,703,000 (107,636,000)   $ (96,903,000) 20,994,000 (15,994,000) $ 5,000,000
Balance at the beginning (in shares) at Mar. 31, 2021   30,182,983              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of stock options   $ 5,000 197,000     202,000      
Issuance of common stock upon exercise of stock options (in shares)   5,159,411              
Stock-based compensation expense     535,000     535,000      
Net loss attributable to common stockholders - basic and diluted       (22,371,000)   (22,371,000)   (7,626,000) (7,626,000)
Balance at the end at Jun. 30, 2021   $ 35,000 $ 11,435,000 $ (130,007,000)   $ (118,537,000) $ 28,620,000 $ (23,620,000) $ 5,000,000
Balance at the end (in shares) at Jun. 30, 2021   35,342,394